Spyre Therapeutics, Inc. SYRE Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Returns | ||||||
| Return on equity | -31.1%-5.9pp | -25.2%+12.9pp | -38.1%— | —— | —— | |
| Liquidity | ||||||
| Current ratio | 9×-4.3× | 13.3×+2.3× | 10.9×+4.4× | 6.5×-1.6× | 8.1×-3.2× | |
| Per Share | ||||||
| Book value per share | $8.54-23.5% | $11.17+48.2% | $7.53-0.3% | $7.55-5.7% | $8.01-27.3% | |
| Valuation | ||||||
| Market capitalization | $3.96B+55.8% | $2.54B+151% | $1.01B+8.8% | $930.05M-4.3% | $972.25M-30.2% | |
| Price / book | 5.9×+2.4× | 3.6×+1.3× | 2.2×+0.2× | 2×0.0× | 2×-0.7× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Spyre Therapeutics, Inc.'s ratios come from?
- Every ratio is computed from Spyre Therapeutics, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.